-
公开(公告)号:US20240288430A1
公开(公告)日:2024-08-29
申请号:US18513107
申请日:2023-11-17
发明人: Craig Anthony CUMMINGS , Yan LI , Sarah Margaret SHAGAN , Erica Beth SCHLEIFMAN , David SHAMES , David FABRIZIO , Daniel LIEBER , Geoffrey Alan OTTO , Mark KENNEDY , Travis CLARK , Doron LIPSON , Jie HE , Shan ZHONG
IPC分类号: G01N33/574 , A61K39/00 , A61P35/00 , C07K14/735 , C07K16/28 , C12Q1/68 , C12Q1/6883 , G06F16/28 , G16H50/20 , G16H50/30 , G16H50/50 , G16H50/70
CPC分类号: G01N33/574 , A61P35/00 , C07K14/70535 , C07K16/2827 , C07K16/2896 , C12Q1/68 , C12Q1/6883 , G01N33/57492 , G06F16/285 , G16H50/20 , G16H50/30 , G16H50/50 , G16H50/70 , A61K2039/505 , A61K2039/55 , C07K2317/24 , C12Q2600/156 , G01N2333/70532 , G01N2800/52
摘要: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.
-
公开(公告)号:US20190025308A1
公开(公告)日:2019-01-24
申请号:US16041363
申请日:2018-07-20
发明人: Craig Anthony CUMMINGS , Yan LI , Sarah Margaret PAUL , Erica Beth SCHLEIFMAN , David SHAMES , David FABRIZIO , Daniel LIEBER , Geoffrey Alan OTTO , Mark KENNEDY , Travis CLARK , Doron LIPSON , Jie HE , Shan ZHONG
IPC分类号: G01N33/574 , C07K16/28 , G16H50/70 , G16H50/50 , G16H50/30 , G16H50/20 , G06F17/30 , C07K14/735 , A61P35/00
摘要: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.
-